<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Short-lasting unilateral neuralgiform headache attacks: Treatment and prognosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Short-lasting unilateral neuralgiform headache attacks: Treatment and prognosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Short-lasting unilateral neuralgiform headache attacks: Treatment and prognosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Manjit S Matharu, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anna S Cohen, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jerry W Swanson, MD, MHPE
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard P Goddeau, Jr, DO, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 15, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The trigeminal autonomic cephalalgias (TACs) are a group of primary headache disorders characterized by unilateral trigeminal distribution pain that occurs in association with ipsilateral cranial autonomic features [
         <a href="#rid1">
          1,2
         </a>
         ]. The TACs include cluster headache, paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks, and hemicrania continua [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         There are two subtypes of short-lasting unilateral neuralgiform headache attacks [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA)
        </p>
        <p>
        </p>
        <p>
         Although SUNCT and SUNA were once considered to be refractory to therapy, beneficial responses with several medications have been reported in small numbers of patients. However, the evidence consists mainly of case reports and small case series.
        </p>
        <p>
         This topic will review the treatment and prognosis of SUNCT and SUNA. The clinical features and diagnosis of these syndromes are reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3336.html" rel="external">
          "Short-lasting unilateral neuralgiform headache attacks: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
         Other TACs are also discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3326.html" rel="external">
          "Cluster headache: Epidemiology, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3351.html" rel="external">
          "Cluster headache: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3334.html" rel="external">
          "Paroxysmal hemicrania: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3335.html" rel="external">
          "Paroxysmal hemicrania: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3342.html" rel="external">
          "Hemicrania continua"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ACUTE MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest acute therapy with an intravenous
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         infusion for patients with frequently recurring and debilitating attacks of SUNCT or SUNA. For patients who do not respond to or are unable to tolerate a lidocaine infusion, we offer alternative medications used for the acute treatment of other trigeminal autonomic cephalgias (TACs)  (
         <a class="graphic graphic_table graphicRef65541" href="/z/d/graphic/65541.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         For patients with infrequent or less severe attacks, we treat with a preventive medication alone.
        </p>
        <p class="headingAnchor" id="H372431796">
         <span class="h2">
          Frequent and debilitating attacks
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with frequent and debilitating attacks of SUNCT or SUNA, we suggest initial acute therapy with an intravenous
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         infusion. In addition, we typically start a preventive medication after lidocaine infusion has completed to help prevent recurrence of attacks. For those patients already taking a preventive medication, we typically continue this agent during acute infusion therapy to reduce headache recurrence. (See
         <a class="local">
          'Preventive management for all patients'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h3">
          Lidocaine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intravenous
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         may be particularly useful for some patients with SUNCT who experience acute, severe exacerbations characterized by frequent, easily triggered, high-intensity pain [
         <a href="#rid4">
          4,5
         </a>
         ]. Such patients may not be able to eat or drink because these actions trigger attacks, and the need for acute intervention is urgent.
        </p>
        <p>
         Limited data suggest that SUNCT and SUNA are responsive to treatment with parenteral
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         given in the hospital for one to seven days; the supporting evidence comes from small case series [
         <a href="#rid4">
          4-9
         </a>
         ]. Among 15 patients (11 with SUNCT and 4 with SUNA) treated with intravenous lidocaine for up to seven days, partial relief to total abolition of symptoms was observed in 14 patients; 1 patient with SUNCT was lost to follow-up [
         <a href="#rid4">
          4
         </a>
         ]. Pain-free periods were variable; the shortest lasted only as long as the duration of the infusion. The longest pain-free periods were 3 weeks in a patient with chronic SUNCT, 12 weeks in a patient with chronic SUNA, and 6 months in another patient with episodic SUNCT. In another report of 14 patients with SUNCT or SUNA who had 17 attacks treated with lidocaine (14 by subcutaneous infusion and 3 by intravenous infusion), there was complete resolution of pain in 13 attacks (76 percent) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         In addition to rapid amelioration of pain, some patients with a successful response to
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         infusion are pain-free for weeks after the infusion. This may allow a period of time for either a drug-free interval or for titration and optimization of preventive medications. (See
         <a class="local">
          'Preventive management for all patients'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preparation
         </strong>
         – Prior to dosing, patients should have a baseline electrocardiogram (ECG) and liver enzyme and renal function testing. Hypokalemia and hypomagnesemia should be corrected before the drug is given and throughout treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing and monitoring
         </strong>
         – Intravenous
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         is administered in the hospital by continuous infusion (eg, 1.3 to 3.4 mg/kg per hour, titrate as needed to suppress symptoms), with an optional loading dose of 1 mg/kg over 15 minutes [
         <a href="#rid5">
          5
         </a>
         ]. Lower doses should be used in patients with hepatic or kidney function impairment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Continuous ECG monitoring is required during intravenous
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         administration. Hemodynamic parameters should be monitored with initiation and with any increase in the dose according to hospital protocol. We monitor the pulse rate and blood pressure every five minutes for the first 30 minutes, then every 15 minutes for four hours, then every four hours. The total duration of the infusion should not exceed seven days. Lidocaine serum levels should be monitored daily. If the level exceeds 5 mcg/mL (21 micromoles/L) or there are signs of toxicity, the dose should be reduced. (See
         <a class="medical medical_review" href="/z/d/html/86747.html" rel="external">
          "Major side effects of class I antiarrhythmic drugs", section on 'Lidocaine (intravenous)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A response is considered positive if the attacks are mostly or entirely suppressed for the duration of the infusion or longer.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         –
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          Lidocaine
         </a>
         infusion is associated with the potential for serious adverse events, especially when high doses are utilized [
         <a href="#rid7">
          7-9
         </a>
         ]. These events include cardiac arrhythmias, cognitive impairment, dizziness, tremor, nausea, and diarrhea. In addition, we have noted some patients develop neuropsychiatric symptoms such as acute depression or paranoia [
         <a href="#rid10">
          10
         </a>
         ]. While these adverse events always resolve, supportive or symptomatic management may be needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications
         </strong>
         – Intravenous
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         should
         <strong>
          not
         </strong>
         be used in patients with any degree of cardiac conduction system abnormality or heart block who do not have an artificial pacemaker. It is also contraindicated in patients with hypersensitivity to lidocaine or another local anesthetic of the amide type. Lidocaine crosses the placenta; caution is advised for use in pregnancy and during breastfeeding [
         <a href="#rid11">
          11,12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4140199360">
         <span class="h3">
          Alternative acute treatments
         </span>
         <span class="headingEndMark">
          —
         </span>
         For those unresponsive or unable to tolerate
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         , acute treatments used for other TACs, including oxygen [
         <a href="#rid5">
          5,13
         </a>
         ], oral and intramuscular
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         [
         <a href="#rid5">
          5,14-20
         </a>
         ], and occipital nerve blocks [
         <a href="#rid21">
          21
         </a>
         ], may be tried but have not been consistently effective for SUNCT or SUNA.
        </p>
        <p>
         There is no clear benefit to support using simple analgesics, combination analgesics, or opioids for the acute treatment of SUNCT or SUNA [
         <a href="#rid5">
          5,13,22,23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H595751715">
         <span class="h2">
          Infrequent or nondebilitating attacks
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with less severe pain during attacks, those with very brief attacks with long (months) interictal intervals, and those with interictal pain between attacks, we treat with a preventive medication. (See
         <a class="local">
          'Preventive management for all patients'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          PREVENTIVE MANAGEMENT FOR ALL PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         SUNCT and SUNA headaches were once considered to be refractory to treatment. However, data from small open-label studies suggest that
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         , and
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         are moderately effective as preventive therapy for some patients with SUNCT and SUNA  (
         <a class="graphic graphic_table graphicRef65541" href="/z/d/graphic/65541.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1231273426">
         <span class="h2">
          Treatment approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based on available data and clinical experience, we suggest
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         as initial preventive medical therapy for patients with frequent or debilitating attacks of SUNCT or SUNA [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="local">
          'Initial therapy with lamotrigine'
         </a>
         below.)
        </p>
        <p>
         For patients who do not respond to or are unable to tolerate
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         , we use an alternative medication. These medications include
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">
          duloxetine
         </a>
         , and
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         [
         <a href="#rid21">
          21
         </a>
         ]. The data supporting these medications are from case reports and one small trial; comparative efficacy among options is lacking. For most patients, we use patient comorbid conditions and concomitant medications help to select among options. We offer topiramate for those with headache features consistent with SUNCT based on some comparative efficacy data for patients with SUNCT versus those with SUNA [
         <a href="#rid21">
          21,24
         </a>
         ]. (See
         <a class="local">
          'Alternative therapy if lamotrigine ineffective or not tolerated'
         </a>
         below.)
        </p>
        <p>
         Combination therapy may be used for patients who report partial response with monotherapy. In addition, combination therapy may be useful when lower doses of two agents would cause fewer side effects than a higher dose of a single agent. Details about specific drug interactions can be found using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included within UpToDate.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Initial therapy with lamotrigine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          Lamotrigine
         </a>
         is started at 25 mg daily for two weeks, then increased to 50 mg daily for two weeks. The dose may be further titrated as needed and as tolerated. After four weeks, the daily dose can be increased by 50 mg every one to two weeks. The usual maintenance dose is 200 mg daily given in two divided doses, but total daily doses up to 400 mg given in two divided doses have been used.
        </p>
        <p>
         Dose adjustments may be needed for interacting medications.
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          Lamotrigine
         </a>
         levels are markedly increased by an interaction with
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         , which inhibits lamotrigine metabolism, and decreased in the presence of drugs that induce lamotrigine metabolism (including
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          phenobarbital
         </a>
         ,
         <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">
          primidone
         </a>
         , estrogen-containing oral contraceptives,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , and protease inhibitors such as
         <a class="drug drug_general" data-topicid="9982" href="/z/d/drug information/9982.html" rel="external">
          lopinavir-ritonavir
         </a>
         ). These interactions lead to different dosing schemes, as discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Lamotrigine'
         </a>
         .)
        </p>
        <p>
         Systemic side effects of
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         include rash and nausea. A benign rash may develop in up to 10 percent of patients during the initial one to two months of therapy and necessitates discontinuation of the drug. The risk of developing a life-threatening rash such as Stevens-Johnson syndrome, toxic epidermal necrolysis, or angioedema is approximately 1 in 1000 adults; this risk is increased in children. The risk of developing a serious rash may be increased if the initial dose escalation is too rapid.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          Lamotrigine
         </a>
         may be the most effective preventive medication for SUNCT and SUNA. In a prospective, single-center, open-label study, 76 percent of 128 patients improved with lamotrigine and 56 percent reported at least 50 percent reduction in attack frequency [
         <a href="#rid21">
          21
         </a>
         ]. Lamotrigine (up to 300 mg daily) was effective in several other case series and case reports [
         <a href="#rid6">
          6,22,24-28
         </a>
         ]. However, lamotrigine was ineffective in other reports, including patients with chronic SUNCT or SUNA and those with secondary causes of short-lasting unilateral neuralgiform headache pain, such as due to trigeminal nerve compression [
         <a href="#rid6">
          6,15,29,30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3183452741">
         <span class="h2">
          Alternative therapy if lamotrigine ineffective or not tolerated
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alternative agents may be used when patients are unresponsive or unable to tolerate
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         . Data from case reports and systematic reviews suggest benefit with
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">
          duloxetine
         </a>
         , and
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         [
         <a href="#rid21">
          21
         </a>
         ]. The choice among these options is guided by patient comorbidities and the effort to avoid medication interactions.
        </p>
        <p class="headingAnchor" id="H3626716795">
         <span class="h3">
          Oxcarbazepine
         </span>
         <span class="headingEndMark">
          —
         </span>
         In an open-label study, SUNCT and SUNA symptoms improved in 71 percent of patients who received
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         [
         <a href="#rid21">
          21
         </a>
         ]. Nearly 50 percent were responders (at least 50 percent improvement in symptoms compared with baseline). Benefit was also shown in other case reports [
         <a href="#rid31">
          31,32
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          Oxcarbazepine
         </a>
         is typically started at 300 mg twice daily. The dose may be increased by 600 mg each week up to 2400 mg daily as needed and tolerated.
        </p>
        <p>
         Common adverse effects are similar to those of
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         and may include nausea, vomiting, sedation, headache, rash, and hyponatremia.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Topiramate
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          Topiramate
         </a>
         may be useful as a preventive medication for SUNCT and SUNA [
         <a href="#rid4">
          4,24,33
         </a>
         ]. In a single-center, open-label study, 47 percent of 76 patients improved with topiramate and 25 percent reported at least 50 percent reduction in attacks [
         <a href="#rid21">
          21
         </a>
         ]. In two studies, topiramate was more effective for patients with SUNCT than those with SUNA [
         <a href="#rid21">
          21,24
         </a>
         ].
        </p>
        <p>
         The usual starting dose of
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         is 15 to 25 mg daily; the dose can be increased by 25 mg increments every two weeks up to 100 mg total daily in two divided doses, and thereafter by 50 mg increments every few weeks up to 400 mg total daily, if required and tolerated. However, the optimal dose for SUNCT and SUNA is unknown.
        </p>
        <p>
         Common adverse effects include impaired cognition and acral paresthesias. Metabolic acidosis and tachypnea may result from renal bicarbonate loss due to the inhibitory effect of
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         on carbonic anhydrase; patients taking topiramate for prolonged periods may develop kidney stones due to carbonic anhydrase inhibition. Some patients report weight loss. Additional side effects include headache, fatigue, dizziness, depression, and mood problems. Acute myopia and secondary angle closure glaucoma are rare side effects.
        </p>
        <p class="headingAnchor" id="H821851600">
         <span class="h3">
          Carbamazepine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several case series and reports support the effectiveness of
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         for some patients with SUNCT and SUNA [
         <a href="#rid34">
          34-36
         </a>
         ]. In one study, 50 percent of 84 patients who received carbamazepine reported symptom improvement and 26 percent reported 50 percent or greater improvement compared with baseline [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          Carbamazepine
         </a>
         is started at 200 mg twice daily. The dose can be increased by 200 mg weekly up to 1600 mg daily as tolerated.
        </p>
        <p>
         Adverse effects with
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         include nausea, vomiting, diarrhea, hyponatremia, rash, and leukopenia.
        </p>
        <p class="headingAnchor" id="H1583496761">
         <span class="h3">
          Duloxetine
         </span>
         <span class="headingEndMark">
          —
         </span>
         In one study, 49 percent of 37 patients who received
         <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">
          duloxetine
         </a>
         reported symptom improvement and 30 percent reported 50 percent or greater improvement compared with baseline [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">
          Duloxetine
         </a>
         is started at 30 mg daily and can be increased one week later to 60 mg daily. Further weekly increases by 30 mg up to the daily maximum dose is 120 mg can be attempted if needed for optimal effectiveness but higher doses are limited by risk of adverse effects, including abdominal pain, nausea, vomiting, weight loss, fatigue, and headache.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Gabapentin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several case series and reports indicate that
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         may useful as preventive therapy in SUNCT and SUNA [
         <a href="#rid17">
          17,24,37-39
         </a>
         ]. In one study, 33 percent of 80 patients reported some improvement but only 10 percent reported at least 50 percent improvement compared with baseline symptoms [
         <a href="#rid21">
          21
         </a>
         ]. In another series of 27 patients with SUNCT or SUNA, treatment with gabapentin (up to 3600 mg daily) was associated with a good response in 13 (48 percent) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Although regimens vary, we start with an initial dose of 300 mg daily, increasing gradually to 300 mg twice a day and then to 300 mg three times a day. Thereafter, the dose may be increased slowly as needed to 1800 mg a day in three divided doses, although some patients require total doses up to 3600 mg daily. In neuropathic pain conditions, typical maintenance
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         doses range from 900 to 2400 mg/day, and the drug is usually well tolerated at doses up to 3600 mg daily when titrated up cautiously.
        </p>
        <p>
         The major side effect of
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         is sedation. Others include diarrhea, mood swings, ataxia, fatigue, nausea, lower extremity edema, and dizziness.
        </p>
        <p class="headingAnchor" id="H4615814">
         <span class="h3">
          Other medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of other medications, alone or in combination, have been employed to treat SUNCT and SUNA, including
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         [
         <a href="#rid40">
          40,41
         </a>
         ],
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         [
         <a href="#rid5">
          5,19,42,43
         </a>
         ],
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         [
         <a href="#rid20">
          20,44
         </a>
         ],
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ,
         <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">
          zonisamide
         </a>
         [
         <a href="#rid45">
          45
         </a>
         ],
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         (botulinum toxin A) injections [
         <a href="#rid46">
          46
         </a>
         ], and glucocorticoids [
         <a href="#rid13">
          13,16,18,47-49
         </a>
         ]. However, none has been consistently effective.
        </p>
        <p class="headingAnchor" id="H2361934045">
         <span class="h1">
          INVASIVE PROCEDURES FOR REFRACTORY CASES
         </span>
         <span class="headingEndMark">
          —
         </span>
         We reserve invasive procedures for patients who do not achieve satisfactory results with acute and preventive oral medications. Several invasive procedures have been associated with improvement of symptoms in patients with medically refractory SUNCT or SUNA [
         <a href="#rid50">
          50
         </a>
         ]. These take the form either of local blockades, surgical procedures involving the trigeminal nerve, or neuromodulatory procedures.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Greater occipital nerve blockade or stimulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited observational data show some benefit from greater occipital nerve procedures for patients with SUNCT and SUNA [
         <a href="#rid50">
          50
         </a>
         ]. In patients responsive to treatment, pain-free times ranged from one week to six months. In one study, ipsilateral greater occipital nerve block was associated with improvement in 6 of 12 patients with SUNCT and in 3 of 4 patients with SUNA [
         <a href="#rid24">
          24
         </a>
         ]. However, not all reports showed that nerve block was effective for patients with SUNCT and SUNA [
         <a href="#rid43">
          43
         </a>
         ]. In another study, only 11 of 47 patients with SUNCT and 10 of 31 patients with SUNA had a good or excellent effect of greater occipital nerve block [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         Bilateral occipital nerve stimulation was evaluated in a prospective observational study of 31 patients with intractable SUNCT or SUNA [
         <a href="#rid51">
          51
         </a>
         ]. At a median follow-up of 45 months, the mean daily attack frequency decreased from baseline by 69 percent. The rate of adverse events was low.
        </p>
        <p>
         Nociceptive pathways in the head involve an important interaction between trigeminal and cervical afferents in the trigeminocervical complex [
         <a href="#rid52">
          52,53
         </a>
         ]. This mechanism might be involved in the referral of pain from trigeminal to cervical structures. Thus, either greater occipital nerve blockade or stimulation may play a role in modulating these trigeminocervical connections.
        </p>
        <p>
         Though the mechanism of action of the two treatment modalities is poorly understood, they probably work by completely different mechanisms. Greater occipital nerve blockade reduces afferent traffic along the trigeminal-occipital input, while occipital nerve stimulation increases traffic along this pathway and probably acts by bringing about neuroplastic changes in the pain network.
        </p>
        <p>
         Given the small numbers of patients studied, treatment of SUNCT and SUNA with greater occipital nerve procedures (either blockade or stimulation) should be considered investigational.
        </p>
        <p class="headingAnchor" id="H21940101">
         <span class="h2">
          Other local blockades
         </span>
         <span class="headingEndMark">
          —
         </span>
         Local blockades of other pericranial nerves (supraorbital, infraorbital, lacrimal), the retrobulbar region, pericranial ganglia (stellate, pterygopalatine, superior cervical), and orbicularis oculi muscles have generally failed to show durable effectiveness [
         <a href="#rid43">
          43,54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H24030013">
         <span class="h2">
          Trigeminal nerve decompression
         </span>
         <span class="headingEndMark">
          —
         </span>
         Small case reports and studies have suggested that trigeminal microvascular decompression is beneficial for patients with refractory short-lasting unilateral neuralgiform headache attacks who have an abnormal vascular loop in contact with the symptomatic trigeminal nerve at the root entry zone [
         <a href="#rid50">
          50
         </a>
         ]. One of the largest series reported 47 patients with intractable SUNCT or SUNA [
         <a href="#rid55">
          55
         </a>
         ]. At a mean follow-up of 57 months after microvascular decompression, 37 patients (79 percent) reported at least 75 percent reduction in weekly headache frequency. Four patients developed a postoperative cerebrospinal fluid leak requiring surgical repair and three patients developed persistent neuropathic pain at the incision site. Additional studies are required to identify patients likely to respond to this procedure and determine its role in the treatment of patients with SUNCT or SUNA.
        </p>
        <p class="headingAnchor" id="H665672141">
         <span class="h2">
          Procedures not recommended
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Destructive trigeminal nerve procedures
         </strong>
         – In our experience, invasive, destructive trigeminal nerve procedures are of no value or are harmful in patients with SUNCT and SUNA. The available evidence is limited to a few patients who were treated with glycerol rhizotomy, gamma knife radiosurgery, or radiofrequency thermocoagulation of the trigeminal nerve [
         <a href="#rid5">
          5,18,29,56,57
         </a>
         ]. Some experts recommend that trigeminal surgery be considered only as a last resort and then with extreme caution, given its uncertain outcomes and the potential for permanent loss of nerve function. However, our view is that destructive procedures have no place in the current management of SUNCT and SUNA.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Deep brain stimulation
         </strong>
         – Functional imaging studies found that activation of the posterior hypothalamus was linked to attacks of SUNCT [
         <a href="#rid30">
          30,58
         </a>
         ] suggesting that deep brain stimulation (DBS) might be a therapeutic option [
         <a href="#rid59">
          59,60
         </a>
         ]. Other reports suggested that the midbrain tegmentum might be the preferred target of DBS [
         <a href="#rid61">
          61
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3339.html" rel="external">
          "Pathophysiology of the trigeminal autonomic cephalalgias"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In one uncontrolled observational study, 11 patients with refractory short-lasting unilateral neuralgiform headache attacks were treated with ipsilateral DBS targeting the ventral tegmental area of the midbrain [
         <a href="#rid62">
          62
         </a>
         ]. Treatment was associated with a median reduction in daily attack frequency of 78 percent. The response rate, defined as the proportion of patients with a ≥50 percent improvement in daily attack frequency, was 82 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although these results are promising, further study is needed to define the role and utility of DBS for patients with SUNCT and SUNA.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1643305941">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         SUNCT or SUNA may resolve for some patients over a period of months or years but many others may report lifelong persistent or recurrent symptoms. Prognostic data available for other trigeminal autonomic cephalgias suggest many patients may report lifelong symptoms that decrease in frequency with age [
         <a href="#rid63">
          63
         </a>
         ]. However, there are no large-scale observational studies to allow for an accurate estimate of long-term prognosis for patients with SUNCT and SUNA.
        </p>
        <p class="headingAnchor" id="H2414343854">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110285.html" rel="external">
          "Society guideline links: Migraine and other primary headache disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Terminology
         </strong>
         – There are two subtypes of short-lasting unilateral neuralgiform headache attacks (see
         <a class="local">
          'Introduction'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute treatments
         </strong>
         – For patients with acute, frequent, and debilitating attacks of SUNCT or SUNA, we suggest initial therapy with an intravenous
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         infusion (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Continuous electrocardiogram monitoring is required during intravenous lidocaine administration, along with close observation for adverse effects. (See
         <a class="local">
          'Acute management'
         </a>
         above and
         <a class="local">
          'Frequent and debilitating attacks'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients unresponsive or unable to tolerate
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         , acute treatments used for other trigeminal autonomic cephalalgias, including oxygen, oral and intramuscular
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         , and occipital nerve blocks may be tried but have not been consistently effective for SUNCT or SUNA  (
         <a class="graphic graphic_table graphicRef65541" href="/z/d/graphic/65541.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with less severe pain during attacks, those with very brief attacks with long (months) interictal intervals, and those with interictal pain between attacks, we treat with a preventive medication.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preventive treatments
         </strong>
         – For most patients with SUNCT or SUNA, we suggest initial preventive therapy with
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Preventive management for all patients'
         </a>
         above and
         <a class="local">
          'Initial therapy with lamotrigine'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who do not respond to or are unable to tolerate
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         , we use an alternative medication such as
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">
          duloxetine
         </a>
         , or
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         (
         <a class="graphic graphic_table graphicRef65541" href="/z/d/graphic/65541.html" rel="external">
          table 1
         </a>
         ). We use patient comorbid conditions and concomitant medications to help select among options. (See
         <a class="local">
          'Alternative therapy if lamotrigine ineffective or not tolerated'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We reserve invasive procedures for patients who do not achieve satisfactory results with acute and preventive oral medications. Several invasive procedures have been attempted to alleviate SUNCT or SUNA symptoms. These take the form either of local blockades, surgical procedures involving the trigeminal nerve, or neuromodulatory procedures. (See
         <a class="local">
          'Invasive procedures for refractory cases'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – SUNCT or SUNA may resolve for some patients over a period of months or years, but many others may report lifelong persistent or recurrent symptoms. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Goadsby PJ, Lipton RB. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases. Brain 1997; 120 ( Pt 1):193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goadsby PJ. Trigeminal autonomic cephalalgias. Pathophysiology and classification. Rev Neurol (Paris) 2005; 161:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen AS. Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing. Cephalalgia 2007; 27:824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matharu MS, Cohen AS, Goadsby PJ. SUNCT syndrome responsive to intravenous lidocaine. Cephalalgia 2004; 24:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams MH, Broadley SA. SUNCT and SUNA: clinical features and medical treatment. J Clin Neurosci 2008; 15:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991; 41:1024.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrante FM, Paggioli J, Cherukuri S, Arthur GR. The analgesic response to intravenous lidocaine in the treatment of neuropathic pain. Anesth Analg 1996; 82:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace MS, Dyck JB, Rossi SS, Yaksh TL. Computer-controlled lidocaine infusion for the evaluation of neuropathic pain after peripheral nerve injury. Pain 1996; 66:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gil-Gouveia R, Goadsby PJ. Neuropsychiatric side-effects of lidocaine: examples from the treatment of headache and a review. Cephalalgia 2009; 29:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cavalli Rde C, Lanchote VL, Duarte G, et al. Pharmacokinetics and transplacental transfer of lidocaine and its metabolite for perineal analgesic assistance to pregnant women. Eur J Clin Pharmacol 2004; 60:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bjørk MH, Kristoffersen ES, Tronvik E, Egeland Nordeng HM. Management of cluster headache and other trigeminal autonomic cephalalgias in pregnancy and breastfeeding. Eur J Neurol 2021; 28:2443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matharu MS, Cohen AS, Boes CJ, Goadsby PJ. Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing syndrome: a review. Curr Pain Headache Rep 2003; 7:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prakash KM, Lo YL. SUNCT syndrome in association with persistent Horner syndrome in a Chinese patient. Headache 2004; 44:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Köseoglu E, Karaman Y, Kücük S, Arman F. SUNCT syndrome associated with compression of trigeminal nerve. Cephalalgia 2005; 25:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossi P, Cesarino F, Faroni J, et al. SUNCT syndrome successfully treated with topiramate: case reports. Cephalalgia 2003; 23:998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunt CH, Dodick DW, Bosch EP. SUNCT responsive to gabapentin. Headache 2002; 42:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gardella L, Viruega A, Rojas H, Nagel J. A case of a patient with SUNCT syndrome treated with Jannetta procedure. Cephalalgia 2001; 21:996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Volcy M, Tepper SJ, Rapoport AM, et al. Short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA)--a case report. Cephalalgia 2005; 25:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narbone MC, Gangemi S, Abbate M. A case of SUNCT syndrome responsive to verapamil. Cephalalgia 2005; 25:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lambru G, Stubberud A, Rantell K, et al. Medical treatment of SUNCT and SUNA: a prospective open-label study including single-arm meta-analysis. J Neurol Neurosurg Psychiatry 2021; 92:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malik K, Rizvi S, Vaillancourt PD. The SUNCT syndrome: successfully treated with lamotrigine. Pain Med 2002; 3:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Putzki N, Nirkko A, Diener HC. Trigeminal autonomic cephalalgias: a case of post-traumatic SUNCT syndrome? Cephalalgia 2005; 25:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weng HY, Cohen AS, Schankin C, Goadsby PJ. Phenotypic and treatment outcome data on SUNCT and SUNA, including a randomised placebo-controlled trial. Cephalalgia 2018; 38:1554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Andrea G, Granella F, Cadaldini M. Possible usefulness of lamotrigine in the treatment of SUNCT syndrome. Neurology 1999; 53:1609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leone M, Rigamonti A, Usai S, et al. Two new SUNCT cases responsive to lamotrigine. Cephalalgia 2000; 20:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Andrea G, Granella F, Ghiotto N, Nappi G. Lamotrigine in the treatment of SUNCT syndrome. Neurology 2001; 57:1723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gutierrez-Garcia JM. SUNCT syndrome responsive to lamotrigine. Headache 2002; 42:823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Black DF, Dodick DW. Two cases of medically and surgically intractable SUNCT: a reason for caution and an argument for a central mechanism. Cephalalgia 2002; 22:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sprenger T, Valet M, Platzer S, et al. SUNCT: bilateral hypothalamic activation during headache attacks and resolving of symptoms after trigeminal decompression. Pain 2005; 113:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marziniak M, Breyer R, Evers S. SUNCT syndrome successfully treated with the combination of oxcarbazepine and gabapentin. Pain Med 2009; 10:1497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dora B. SUNCT syndrome with dramatic response to oxcarbazepine. Cephalalgia 2006; 26:1171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen AS, Matharu MS, Goadsby PJ. Double-blind placebo-controlled trial of topiramate in SUNCT. Cephalalgia 2007; 27:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raimondi E, Gardella L. SUNCT syndrome. Two cases in Argentina. Headache 1998; 38:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pareja JA, Sjaastad O. SUNCT syndrome in the female. Headache 1994; 34:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pareja JA, Alvarez M, Montojo T. SUNCT and SUNA: Recognition and Treatment. Curr Treat Options Neurol 2013; 15:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Etemadifar M, Maghzi AH, Ghasemi M, et al. Efficacy of gabapentin in the treatment of SUNCT syndrome. Cephalalgia 2008; 28:1339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graff-Radford SB. SUNCT syndrome responsive to gabapentin (Neurontin). Cephalalgia 2000; 20:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porta-Etessam J, Martinez-Salio A, Berbel A, Benito-Leon J. Gabapentin (neuronetin) in the treatment of SUNCT syndrome. Cephalalgia 2002; 22:249; author reply 249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rozen TD, Saper JR, Sheftell FD, Dodick DW. Clomiphene citrate as a new treatment for SUNCT: hormonal manipulation for hypothalamic-influenced trigeminal autonomic cephalalgias. Headache 2005; 45:754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rozen TD. Complete alleviation of treatment refractory primary SUNCT syndrome with clomiphene citrate (a medicinal deep brain hypothalamic modulator). Cephalalgia 2014; 34:1021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sesso RM. SUNCT syndrome or trigeminal neuralgia with lacrimation and conjunctival injection? Cephalalgia 2001; 21:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pareja JA, Kruszewski P, Sjaastad O. SUNCT syndrome: trials of drugs and anesthetic blockades. Headache 1995; 35:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiménez-Huete A, Franch O, Pareja JA. SUNCT syndrome: priming of symptomatic periods and worsening of symptoms by treatment with calcium channel blockers. Cephalalgia 2002; 22:812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikawa M, Imai N, Manaka S. A case of SUNCT syndrome responsive to zonisamide. Cephalalgia 2011; 31:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zabalza RJ. Sustained response to botulinum toxin in SUNCT syndrome. Cephalalgia 2012; 32:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montes E, Alberca R, Lozano P, et al. Statuslike SUNCT in two young women. Headache 2001; 41:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calvo JF, Bruera OC, de Lourdes Figuerola M, et al. SUNCT syndrome: clinical and 12-year follow-up case report. Cephalalgia 2004; 24:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trauninger A, Alkonyi B, Kovács N, et al. Methylprednisolone therapy for short-term prevention of SUNCT syndrome. Cephalalgia 2010; 30:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smit RD, Mouchtouris N, Kang K, et al. Short-lasting unilateral neuralgiform headache attacks (SUNCT/SUNA): a narrative review of interventional therapies. J Neurol Neurosurg Psychiatry 2023; 94:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller S, Watkins L, Matharu M. Long-term follow up of intractable chronic short lasting unilateral neuralgiform headache disorders treated with occipital nerve stimulation. Cephalalgia 2018; 38:933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goadsby PJ. Migraine pathophysiology. Headache 2005; 45 Suppl 1:S14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goadsby PJ, Bartsch T, Dodick DW. Occipital nerve stimulation for headache: mechanisms and efficacy. Headache 2008; 48:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sabatowski R, Huber M, Meuser T, Radbruch L. SUNCT syndrome: a treatment option with local opioid blockade of the superior cervical ganglion? A case report. Cephalalgia 2001; 21:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lambru G, Lagrata S, Levy A, et al. Trigeminal microvascular decompression for short-lasting unilateral neuralgiform headache attacks. Brain 2022; 145:2882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hannerz J, Linderoth B. Neurosurgical treatment of short-lasting, unilateral, neuralgiform hemicrania with conjunctival injection and tearing. Br J Neurosurg 2002; 16:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams M, Bazina R, Tan L, et al. Microvascular decompression of the trigeminal nerve in the treatment of SUNCT and SUNA. J Neurol Neurosurg Psychiatry 2010; 81:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab 1999; 19:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leone M, Franzini A, D'Andrea G, et al. Deep brain stimulation to relieve drug-resistant SUNCT. Ann Neurol 2005; 57:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyons MK, Dodick DW, Evidente VG. Responsiveness of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing to hypothalamic deep brain stimulation. J Neurosurg 2009; 110:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matharu MS, Zrinzo L. Deep brain stimulation in cluster headache: hypothalamus or midbrain tegmentum? Curr Pain Headache Rep 2010; 14:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller S, Akram H, Lagrata S, et al. Ventral tegmental area deep brain stimulation in refractory short-lasting unilateral neuralgiform headache attacks. Brain 2016; 139:2631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matharu M. Cluster headache. BMJ Clin Evid 2010; 2010.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3338 Version 27.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9055807" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16141962" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Trigeminal autonomic cephalalgias. Pathophysiology and classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29368949" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17598764" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15482363" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : SUNCT syndrome responsive to intravenous lidocaine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18325769" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : SUNCT and SUNA: clinical features and medical treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1712433" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8712433" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The analgesic response to intravenous lidocaine in the treatment of neuropathic pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8857633" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Computer-controlled lidocaine infusion for the evaluation of neuropathic pain after peripheral nerve injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19250287" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Neuropsychiatric side-effects of lidocaine: examples from the treatment of headache and a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15365654" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Pharmacokinetics and transplacental transfer of lidocaine and its metabolite for perineal analgesic assistance to pregnant women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33852763" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Management of cluster headache and other trigeminal autonomic cephalalgias in pregnancy and breastfeeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12828881" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing syndrome: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15012664" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : SUNCT syndrome in association with persistent Horner syndrome in a Chinese patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15910575" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : SUNCT syndrome associated with compression of trigeminal nerve.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14984234" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : SUNCT syndrome successfully treated with topiramate: case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12167143" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : SUNCT responsive to gabapentin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11843874" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A case of a patient with SUNCT syndrome treated with Jannetta procedure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15910574" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA)--a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15910576" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A case of SUNCT syndrome responsive to verapamil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33361408" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Medical treatment of SUNCT and SUNA: a prospective open-label study including single-arm meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15102166" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The SUNCT syndrome: successfully treated with lamotrigine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15839855" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Trigeminal autonomic cephalalgias: a case of post-traumatic SUNCT syndrome?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29096522" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Phenotypic and treatment outcome data on SUNCT and SUNA, including a randomised placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10534285" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Possible usefulness of lamotrigine in the treatment of SUNCT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11167916" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Two new SUNCT cases responsive to lamotrigine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11706123" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Lamotrigine in the treatment of SUNCT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12390648" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : SUNCT syndrome responsive to lamotrigine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12047459" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Two cases of medically and surgically intractable SUNCT: a reason for caution and an argument for a central mechanism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15661452" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : SUNCT: bilateral hypothalamic activation during headache attacks and resolving of symptoms after trigeminal decompression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19863743" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : SUNCT syndrome successfully treated with the combination of oxcarbazepine and gabapentin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16919074" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : SUNCT syndrome with dramatic response to oxcarbazepine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Double-blind placebo-controlled trial of topiramate in SUNCT
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9630790" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : SUNCT syndrome. Two cases in Argentina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8014038" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : SUNCT syndrome in the female.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23242780" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : SUNCT and SUNA: Recognition and Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18727639" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Efficacy of gabapentin in the treatment of SUNCT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11037748" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : SUNCT syndrome responsive to gabapentin (Neurontin).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12047467" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Gabapentin (neuronetin) in the treatment of SUNCT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15953310" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Clomiphene citrate as a new treatment for SUNCT: hormonal manipulation for hypothalamic-influenced trigeminal autonomic cephalalgias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24662321" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Complete alleviation of treatment refractory primary SUNCT syndrome with clomiphene citrate (a medicinal deep brain hypothalamic modulator).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11422099" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : SUNCT syndrome or trigeminal neuralgia with lacrimation and conjunctival injection?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7721573" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : SUNCT syndrome: trials of drugs and anesthetic blockades.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12485207" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : SUNCT syndrome: priming of symptomatic periods and worsening of symptoms by treatment with calcium channel blockers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21036860" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A case of SUNCT syndrome responsive to zonisamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22734103" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Sustained response to botulinum toxin in SUNCT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11576210" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Statuslike SUNCT in two young women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15377323" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : SUNCT syndrome: clinical and 12-year follow-up case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19673911" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Methylprednisolone therapy for short-term prevention of SUNCT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35977820" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Short-lasting unilateral neuralgiform headache attacks (SUNCT/SUNA): a narrative review of interventional therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28708008" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Long-term follow up of intractable chronic short lasting unilateral neuralgiform headache disorders treated with occipital nerve stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15833086" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Migraine pathophysiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18234048" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Occipital nerve stimulation for headache: mechanisms and efficacy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11422100" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : SUNCT syndrome: a treatment option with local opioid blockade of the superior cervical ganglion? A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35325067" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Trigeminal microvascular decompression for short-lasting unilateral neuralgiform headache attacks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11926467" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Neurosurgical treatment of short-lasting, unilateral, neuralgiform hemicrania with conjunctival injection and tearing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20462914" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Microvascular decompression of the trigeminal nerve in the treatment of SUNCT and SUNA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10027765" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15929061" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Deep brain stimulation to relieve drug-resistant SUNCT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18821829" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Responsiveness of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing to hypothalamic deep brain stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20425205" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Deep brain stimulation in cluster headache: hypothalamus or midbrain tegmentum?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27524793" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Ventral tegmental area deep brain stimulation in refractory short-lasting unilateral neuralgiform headache attacks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21718584" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Cluster headache.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
